PubMed Health⌕ Search

Biomedical subjects

J A de Torres Mateos

Publications and source records attributed to J A de Torres Mateos.

At least 19 recordsLinked to original sources
PubMed1999

[Analysis of free PSA percentage predicting potential surgical failure in patients treated with radical prostatectomy].

OBJECTIVE: To analyze if free PSA percentage can help to predict a potential surgical failure (PSF) in patients undergoing radical prostatectomy. MATERIAL AND METHODS: Analysis of serum PSA concentration and free PSA percentage in 92 patients undergoing retropubic radical prostatectomy. In 38 cases, the carcinoma was organ-confined, 26 had capsule penetration, 20 had positive margins, 6 seminal vesicle invasion and 2 lymph nodes. PSF was demonstrated in 28 patients (30.4%) and in 64 (69.6%) the carcinoma was organ-confined. RESULTS: No significant relationship was found between PSA serum concentration or free PSA percentage to the pathological stage. The logistic regression analysis where the clinical status, Gleason sum, and free PSA percentage were included as predictive variables, showed that the latter was the only factor with capacity for PSF prediction. Over all, the probability of a carcinoma being confined in the surgical specimen when percentage of free PSA was greater than 10 was 83.8% and 60% when it was lower or equal, p < 0.03. However, the distribution was only significant when PSA concentration ranged between 4.1 and 10 ng/mL, p < 0.008. In this range of PSA, the relative risk of PSF was 5.5 (95% CI 1.4-21.8) when free PSA percentage was equal or lower than 10, the probability being 50% versus 9.1% when it was greater than 10. CONCLUSIONS: Free PSA percentage can help to predict PSF. PSA serum concentration lower than 10 ng/mL and free PSA percentage greater than 10 allows to detect a subgroup of patients with good prognosis and with less than 10% probability of having positive margins, seminal vesicles invasion or lymph nodes.

Aged↗
PubMed1996

[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].

OBJECTIVES: The combination of carboplatin, methotrexate and vinblastine (M-CAVI) is an active and well-tolerated regimen for patients with bladder cancer who are ineligible for cisplatin-based regimens. We have prospectively randomized patients with locally advanced (T2-4 N0 M0) or locoregional (Tx N1 M0) bladder cancer suitable for subsequent surgical treatment to M-VAC or M-CAVI chemotherapy. METHODS: M-CAVI consisted of carboplatin (300 mg/m2 on day 1 and later adjusted to 4.5 mg/dl/min according to Calvert's formula), methotrexate (30 mg/m2 on days 1, 15 and 22) and vinblastine (3 mg/m2 on days 1, 15 and 22). After 3-4 cycles, the patients were assessed for surgical resection. RESULTS: To date, 60 patients have been included. There were 58 completely evaluable patients, 27 were randomized to M-VAC and 31 to M-CAVI. The overall response rates were similar for M-VAC (48%; confidence interval 95%, 26%-67%) and M-CAVI (45%; confidence interval 95%, 28%-62%). The pathological complete responses were similar for the M-VAC and M-CAVI regimens for both the group with locally advanced (27% vs 39%, p = NS) and locoregional (14% vs 14%, p = NS) bladder cancer. The median actuarial survival for the M-VAC treated group was 23 months and 18 months for the M-CAVI. M-VAC therapy was statistically significantly associated with more events of granulocytopenic fever, grade 2-3 nausea and vomiting, grade 2 alopecia and grade 3-4 mucositis. CONCLUSIONS: The results achieved in the 60 patients included in the study indicate that M-CAVI is better tolerated than M-VAC, although both treatment regimens have similar overall response rates, pathological response rates and survival in patients with locally advanced and locoregional bladder cancer.

Adolescent↗
PubMed1994

[PSA in women. Evaluation of its determination with polyclonal and monoclonal immunoassay].

PSA concentrations were measured in 421 women. In a first group comprising 309 subjects, the assay was carried out with kits containing polyclonal antibodies (PPSA). In the second group with 112 women, the assays used kits containing polyclonal antibodies (PPSA) and kits containing monoclonal antibodies (MPSA), and results obtained with both assays were compared. In the first group PSA levels higher than 0.4 ng/ml were detected in 47.9%. In the second group concentrations higher than 0.4 ng/ml were detected in 52.7% when using PPSA versus 16.7% when using MPSA. The rate of PSA detectable levels in healthy women, with benignant and malignant conditions was 36.7, 42.1 and 84.4% for PPSA, and 16.7, 14.0 and 21.9 for MPSA. This study shows that it is possible to detect PSA levels in women, and that this is more frequent when using a polyclonal antibodies assay.

Adolescent↗
PubMed1993

[Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].

Analysis of the evolution of 78 patients with hormonally-treated non-metastatic prostate cancer. During an average follow-up of 62.3 months, local clinical and metastatic progression in 14.1% and 7.7% cases, respectively, was observed. Overall, PSA detected progression of disease in 94.1% cases, with an anticipation which range between 4 and 52 months. Evidence of bone metastatic progression was confirmed in 2.1% of the 286 scintigraphies performed. Following analysis of results, by accepting their indication from a PSA level higher than 100 ng/ml, 97.9% would have been avoided, achieving a 100% sensitivity and 94.1% diagnostic efficacy.

Aged↗
PubMed1993

[The urological complications of anticoagulant therapy].

Patients on anticoagulant therapy may develop urologic complications, the most common being hematuria. Other less common but more severe complications are spontaneous hemorrhage arising from urological structures, as spontaneous perirenal hematoma, or from extra-urological structures, such as the iliac psoas muscle or the anterior rectus abdominis muscle. We report on four patients on anticoagulant therapy for different reasons, with no previous history of trauma, who suddenly developed spontaneous bleeding with urologic consequences: spontaneous perirenal hematoma (2), hematoma of the iliac muscle (1) and the anterior rectus abdominis muscle (1). The diagnostic strategy, the usefulness of the different imaging techniques and our approach to these complications are discussed.

Aged↗
PubMed1993

[Does transurethral resection cause metastatic dissemination of hormone treated prostatic cancer?].

The evolution of non-metastatic prostate cancer treated with hormonal therapy does not appear to be affected by the performance of a transurethral resection (TUR) as a measure to expedite the common urinary tract. Of 82 patients followed for an interval ranging from 6 months to 15 years, 3 of 45 patients (6.7%) undergoing RUT experienced metastatic dissemination, while the same happened in 2 of 37 (5.4%) patients who did not undergo RUT, p being NS. The group of patients requiring RUT, however, experienced higher local progression rates, 22.2% vs 5.4%, a situation not ascribable to the RUT procedure but to the fact that such surgery was selectively indicated in neoplasias with larger tumoral mass.

Adenocarcinoma↗
PubMed1992

[Value of prostate-specific antigen as prognostic factor of metastatic cancer of the prostate].

This paper examines the behaviour of PSA in 70 patients with metastatic prostate cancer. PSA serum concentration, prior to therapy, was directly related to the tumoral mass and inversely related to the histological degree, which does not constitute a prognostic factor with regard to the disease evolution. Within 3 months of therapy, PSA concentration decreased more noticeably in clinically responding patients, down to less than 10 ng/ml in 93% of them. Also, this level represented a prognostic factor with regard to the free-of-progression interval of the disease.

Aged↗
PubMed1992

[Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer].

Evaluation of results obtained in 70 hormone-treated patients with disseminated prostate cancer. Thirty-six of them were treated via orchiectomy and 34 received also flutamide. Initial objective response rates were 47% in the monotherapy group versus 58% for those undergoing complete blockade. Decrease of PSA and PAP was also higher in the group given flutamide. Nonetheless, no significant changes were observed with regard to biological and clinical progression or patients survival.

Drug Evaluation↗
PubMed1989

[Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].

The authors analyzed 3,079 serum determinations for prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) that had been performed in 1,470 patients. The control group was comprised of 370 patients, 444 comprised the patient group with benign non-prostatic disease, 201 had malignant nonprostatic disease, 290 had benign prostatic disease (85 uncomplicated benign prostatic hypertrophy, 125 complicated benign prostatic hypertrophy, 50 acute prostatitis, 30 chronic prostatitis), 78 had untreated prostate carcinoma, and 165 were patients with prostate carcinoma under treatment. Quantification of PSA and PAP was performed by double antibody radioimmunoassay. The upper limit for normal values was set at 10 ng/ml. for PSA and 2.5 ng/ml. for PAP. Statistical analyses were performed with a personal computer using the SPSC program. Non-parametric tests were utilized throughout in the absence of a normal distribution of values for both tumor markers. In the control group, no significant differences in PSA and PAP levels were observed relative to the age group for the female patients; however, for the male patients, a significant increase was observed after age 15 for both markers. Furthermore, after age 50 PAP values became stable whereas a slight increase was observed for PSA. With regard to tumor mass, a significant correlation was found between PSA levels and the different patient groups while no remarkable differences were observed for PAP levels in those patients without or with single metastasis. We can conclude from the foregoing findings that PSA is currently the most useful tumor marker in diagnosing, staging, and monitoring prostate cancer. However, we believe that PSA and PAP are different manifestations of the prostate cell.(ABSTRACT TRUNCATED AT 250 WORDS)

Acid Phosphatase↗
PubMed1988

Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.

We assayed prostatic specific antigen and prostatic acid phosphatase serum levels in 1,383 patients using a double antibody radioimmunoassay (RIA) 125I. Establishing the upper normal limit in 10 ng/ml for prostatic specific antigen and 2.5 ng/ml for prostatic acid phosphatase, the false positive results were only 1.9 and 5.1% in men with nonprostatic benign or malignant pathology and 0 and 2.2% in women, respectively. We detected false positive levels in 3.5 and 4.7% of the patients with noncomplicated benign prostatic hypertrophy, 64.8 and 19.2% in complicated benign prostatic hypertrophy, 24 and 16% in acute prostatitis and 3.3% in chronic prostatitis for both tumoral markers. The sensibility in patients with prostate cancer was 87.2 and 64.1%, respectively, and there was better correlation with prostatic specific antigen than prostatic acid phosphatase levels on tumoral spread and histologic grading. Finally, the clinical efficacy was higher with prostatic specific antigen and it did not increase with the quantification of both tumoral markers.

Acid Phosphatase↗
PubMed1976

[Physiopathology of spontaneous extravasation of urine in the upper urinary tract. Apropos of 24 cases].

Extravasation of urine was seen in 24 intravenous pyelograms taken for renal colic during the year 1973-74. A number of the patients presented with an acute abdomen. Extravasation took place of retained urine under pressure in the renal pelvis with leakage either around the clayces, from a fissure in the pelvis or even around the ureter. Extravasations of this type are in general rabsorbed without trace. In 5 cases, operation was necessary to drain a purulent collection which had developed in association with the extravasated urine.

Abdomen, Acute↗
PubMedDate not supplied

[Extragonadal germ-cell tumors located in the mediastinum].

INTRODUCTION: The extragonadal germ-cell tumors (EGGCT) represent 5% of all germ-cell tumors at presentation. Histologically, they are identical to testis germ cell tumors. They may arise in such sites as the mediastinum, retroperitoneal area, sacrococcygeal area, or pineal area without a primary in the testis. MATERIAL AND METHODS: The medical records of 10 patients with mediastinal EGGCT were reviewed between 1973 and 1996. All patients were males and his mean age was 26.7 years old (21-24). Follow-up was 19 months (3-72). RESULTS: The first symptoms are diverse. The histology results nonseminomatous tumor at 9 patients and seminomatous tumor at the restant. All of the scrotal examination was normal and only five patients presented increased tumoral markers (alpha-FP in 4 and beta-HCG in 1). Previous at 1990 didn't exist a standard treatment, resulting the four patients treated in this period exitus. After 1990 the treatment was cisplatin-based chemotherapy: BEP (bleomicyn, etoposide-VP-16- and cisplatin-CDDP) then we obtained the best results, a patient died after 6 months but the restants five are alive and without evidence of disease during a follow-up between 3 and 72 months.

Adult↗